CD28 and neoplasm: As observed for the 4-1BB domain-containing CAR, the CD28 domain-containing CAR also exhibited more potent killing and CAR T cells propagated more robustly in the presence of target tumor cells when the CAR expression was driven by the TCRA or TCRB 3’-UTRs (Figure 6—figure supplement 6B and C).